Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
It is expected that addition of anti-CD20 antibody - ofatumumab would enhance the activity of
the etoposide+ifosphamide with mesna+cytarabine+methotrexate+lenograstim or filgrastim (IVAC)
regimen. This study is planned to determine the efficacy and safety of ofatumumab in
combination with IVAC chemotherapy in patients with CD20 positive diffuse large B cell
lymphoma progressing or relapsed after prior R-CHOP chemotherapy not suitable for Autologous
Stem Cell Transplant (ASCT).